{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:56:37Z","timestamp":1770537397163,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1479-5876-11-292","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T00:20:55Z","timestamp":1384993255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase"],"prefix":"10.1186","volume":"11","author":[{"given":"Valentina","family":"Masola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Zaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Granata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Gambaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Onisto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Lupo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"issue":"11","key":"1674_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1111\/j.1600-6143.2008.02391.x","volume":"8","author":"EK Geissler","year":"2008","unstructured":"Geissler EK, Schlitt HJ, Thomas G: mTOR, cancer, and transplantation. Am J Transplant. 2008, 8 (11): 2212-2218.","journal-title":"Am J Transplant"},{"issue":"10","key":"1674_CR2","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1016\/j.transproceed.2007.09.008","volume":"39","author":"JR Chapman","year":"2007","unstructured":"Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A: Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc. 2007, 39 (10): 2937-2950.","journal-title":"Transplant Proc"},{"issue":"5","key":"1674_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","volume":"31","author":"SN Sehgal","year":"1998","unstructured":"Sehgal SN: Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunnuosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998, 31 (5): 335-340.","journal-title":"Clin Biochem"},{"issue":"13","key":"1674_CR4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa042831","volume":"352","author":"G Stallone","year":"2005","unstructured":"Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for Kaposi\u2019s sarcoma in renal-transplant recipients. N Engl J Med. 2005, 352 (13): 1317-1323.","journal-title":"N Engl J Med"},{"issue":"6","key":"1674_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/sj.bjc.6604921","volume":"100","author":"XB Trinh","year":"2009","unstructured":"Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, Van Dam PA: The VEGF pathway and the AKT\/mTOR\/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer. 2009, 100 (6): 971-978.","journal-title":"Br J Cancer"},{"issue":"4","key":"1674_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/0971-5851.76197","volume":"31","author":"SH Advani","year":"2010","unstructured":"Advani SH: Targeting mTOR pathway: a new concept in cancer therapy. Indian J Med Paediatr Oncol. 2010, 31 (4): 132-136.","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"4","key":"1674_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1172\/JCI44145","volume":"121","author":"SA Wander","year":"2011","unstructured":"Wander SA, Hennessy BT, Slingerland JM: Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011, 121 (4): 1231-1241.","journal-title":"J Clin Invest"},{"key":"1674_CR8","first-page":"217","volume":"5","author":"P Cen","year":"2012","unstructured":"Cen P, Amato RJ: Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. Onco Targets Ther. 2012, 5: 217-224.","journal-title":"Onco Targets Ther"},{"issue":"Pt 1","key":"1674_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1469-1809.2003.00012.x","volume":"67","author":"DJ Kwiatkowski","year":"2003","unstructured":"Kwiatkowski DJ: Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet. 2003, 67 (Pt 1): 87-96.","journal-title":"Ann Hum Genet"},{"issue":"Suppl 3","key":"1674_CR10","doi-asserted-by":"crossref","first-page":"iii18","DOI":"10.1093\/ndt\/gfl300","volume":"21","author":"J Pascual","year":"2006","unstructured":"Pascual J: Everolimus in clinical practice\u2013renal transplantation. Nephrol Dial Transplant. 2006, 21 (Suppl 3): iii18-iii23.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1674_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1517\/14740338.2013.752814","volume":"12","author":"N Pallet","year":"2013","unstructured":"Pallet N, Legendre C: Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf. 2013, 12 (2): 177-186.","journal-title":"Expert Opin Drug Saf"},{"issue":"8 Suppl","key":"1674_CR12","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/TP.0b013e3181a05b7a","volume":"87","author":"G Stallone","year":"2009","unstructured":"Stallone G, Infante B, Grandaliano G, Gesualdo L: Management of side effects of sirolimus therapy. Transplantation. 2009, 87 (8 Suppl): S23-S26.","journal-title":"Transplantation"},{"issue":"9","key":"1674_CR13","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","volume":"47","author":"C Porta","year":"2011","unstructured":"Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ: Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2011, 47 (9): 1287-1298.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1674_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/00007890-200109150-00008","volume":"72","author":"E Morelon","year":"2001","unstructured":"Morelon E, Stern M, Israel B, Correas JM, Danel C, Mamzer-Bruneel MF, Peraldi MN, Kreis H: Characteristics of sirolimus associated interstitial pneumonitis in renal transplant patient. Transplantation. 2001, 72 (5): 787-790.","journal-title":"Transplantation"},{"issue":"8","key":"1674_CR15","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1016\/j.transproceed.2010.07.066","volume":"42","author":"P Errasti","year":"2010","unstructured":"Errasti P, Izquierdo D, Mart\u00edn P, Errasti M, Slon F, Romero A, Lavilla FJ: Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc. 2010, 42 (8): 3053-3054.","journal-title":"Transplant Proc"},{"issue":"6","key":"1674_CR16","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.transproceed.2009.06.003","volume":"41","author":"A Rodr\u00edguez-Moreno","year":"2009","unstructured":"Rodr\u00edguez-Moreno A, Ridao N, Garc\u00eda-Ledesma P, Calvo N, P\u00e9rez-Flores I, Marques M, Barrientos A, S\u00e1nchez-Fructuoso AI: Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc. 2009, 41 (6): 2163-2165.","journal-title":"Transplant Proc"},{"issue":"10","key":"1674_CR17","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1093\/ndt\/gfn401","volume":"23","author":"S Alexandru","year":"2008","unstructured":"Alexandru S, Ortiz A, Baldovi S, Milicua JM, Ru\u00edz-Escribano E, Egido J, Plaza JJ: Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant. 2008, 23 (10): 3353-3355.","journal-title":"Nephrol Dial Transplant"},{"key":"1674_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/rr175","volume":"3","author":"M Selman","year":"2002","unstructured":"Selman M, Pardo A: Idiopathic pulmonary fibrosis: an epithelial\/fibroblastic cross-talk disorder. Respir Res. 2002, 3: 3-","journal-title":"Respir Res"},{"issue":"4","key":"1674_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1600-6143.2009.02558.x","volume":"9","author":"S Hodge","year":"2009","unstructured":"Hodge S, Holmes M, Banerjee B, Musk M, Kicic A, Waterer G, Reynolds PN, Hodge G, Chambers DC: Post-transplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am J Transplant. 2009, 9 (4): 727-733.","journal-title":"Am J Transplant"},{"key":"1674_CR20","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.healun.2004.02.018","volume":"24","author":"C Ward","year":"2005","unstructured":"Ward C, Forrest IA, Murphy DM, Johnson GE, Robertson H, Cawston TE: Epithelial to mesenchymal transition in clinically stable lung transplant recipients. J Heart Lung Transpl. 2005, 24: S48-S49.","journal-title":"J Heart Lung Transpl"},{"issue":"3","key":"1674_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1172\/JCI0215518","volume":"110","author":"M Iwano","year":"2002","unstructured":"Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 2002, 110 (3): 341-350.","journal-title":"J Clin Invest"},{"issue":"2","key":"1674_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1681\/ASN.2008121226","volume":"21","author":"Y Liu","year":"2010","unstructured":"Liu Y: New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010, 21 (2): 212-222.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"1674_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00041552-200301000-00005","volume":"12","author":"HY Lan","year":"2003","unstructured":"Lan HY: Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens. 2003, 12 (1): 25-29.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"9","key":"1674_CR24","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1681\/ASN.2006050525","volume":"17","author":"WC Burns","year":"2006","unstructured":"Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P: Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol. 2006, 17 (9): 2484-2494.","journal-title":"J Am Soc Nephrol"},{"issue":"8 Suppl 3","key":"1674_CR25","doi-asserted-by":"publisher","first-page":"S246","DOI":"10.1097\/01.ASN.0000077411.98742.54","volume":"14","author":"H Ha","year":"2003","unstructured":"Ha H, Lee HB: Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol. 2003, 14 (8 Suppl 3): S246-S249.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1674_CR26","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1074\/jbc.M111.279836","volume":"287","author":"V Masola","year":"2012","unstructured":"Masola V, Gambaro G, Tibaldi E, Brunati AM, Gastaldello A, D\u2019Angelo A, Onisto M, Lupo A: Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem. 2012, 287 (2): 1478-1488.","journal-title":"J Biol Chem"},{"issue":"8","key":"1674_CR27","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.bbamcr.2011.05.004","volume":"1813","author":"V Masola","year":"2011","unstructured":"Masola V, Gambaro G, Tibaldi E, Onisto M, Abaterusso C, Lupo A: Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim Biophys Acta. 2011, 1813 (8): 1475-1482.","journal-title":"Biochim Biophys Acta"},{"key":"1674_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/1479-5876-10-213","volume":"10","author":"V Masola","year":"2012","unstructured":"Masola V, Onisto M, Zaza G, Lupo A, Gambaro G: A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med. 2012, 10: 213-","journal-title":"J Transl Med"},{"issue":"5","key":"1674_CR29","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/sj.ki.5002337","volume":"72","author":"MJ Van den Hoven","year":"2007","unstructured":"Van den Hoven MJ, Rops AL, Vlodavsky I, Levidiotis V, Berden JH, Van der Vlag J: Heparanase in glomerular diseases. Kidney Int. 2007, 72 (5): 543-548.","journal-title":"Kidney Int"},{"issue":"7","key":"1674_CR30","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1093\/ndt\/gfr732","volume":"27","author":"AL Rops","year":"2012","unstructured":"Rops AL, Van den Hoven MJ, Veldman BA, Salemink S, Vervoort G, Elving LD, Aten J, Wetzels JF, Van der Vlag J, Berden JH: Urinary heparanase activity in patients with type 1 and type 2 diabetes. Nephrol Dial Transplant. 2012, 27 (7): 2853-2861.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"1674_CR31","doi-asserted-by":"publisher","first-page":"e44076","DOI":"10.1371\/journal.pone.0044076","volume":"7","author":"I Shafat","year":"2012","unstructured":"Shafat I, Agbaria A, Boaz M, Schwartz D, Baruch R, Nakash R, Ilan N, Vlodavsky I, Weinstein T: Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS One. 2012, 7 (9): e44076-","journal-title":"PLoS One"},{"issue":"1","key":"1674_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2353\/ajpath.2010.090517","volume":"176","author":"BD Humphreys","year":"2010","unstructured":"Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010, 176 (1): 85-97.","journal-title":"Am J Pathol"},{"issue":"8","key":"1674_CR33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nm.3218","volume":"19","author":"VS LeBleu","year":"2013","unstructured":"LeBleu VS, Taduri G, O\u2019Connell J, Teng Y, Cooke VG, Woda C, Sugimoto H, Kalluri R: Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013, 19 (8): 1047-1053.","journal-title":"Nat Med"},{"issue":"12","key":"1674_CR34","doi-asserted-by":"publisher","first-page":"e51136","DOI":"10.1371\/journal.pone.0051136","volume":"7","author":"CJ Gr\u00f6ger","year":"2012","unstructured":"Gr\u00f6ger CJ, Grubinger M, Waldh\u00f6r T, Vierlinger K, Mikulits W: Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One. 2012, 7 (12): e51136-","journal-title":"PLoS One"},{"issue":"16","key":"1674_CR35","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.1530509100","volume":"100","author":"JD Storey","year":"2003","unstructured":"Storey JD, Tibshirani R: Statistical significance for genome wide studies. Proc Natl Acad Sci U S A. 2003, 100 (16): 9440-9445.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1674_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1034\/j.1600-6143.2002.20507.x","volume":"2","author":"JM Morales","year":"2002","unstructured":"Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, N\u00e8gre E, Burke JT, Groth CG: Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant. 2002, 2 (5): 436-442.","journal-title":"Am J Transplant"},{"issue":"4 Suppl 2","key":"1674_CR37","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/ajkd.2001.27504","volume":"38","author":"JA Velosa","year":"2001","unstructured":"Velosa JA, Larson TS, Gloor JM, Stegall MD: Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. Am J Kidney Dis. 2001, 38 (4 Suppl 2): S3-S10.","journal-title":"Am J Kidney Dis"},{"key":"1674_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-3-540-31209-3_7","volume":"172","author":"A Boulay","year":"2007","unstructured":"Boulay A, Lane HA: The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results Cancer Res. 2007, 172: 99-124.","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"1674_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 2007, 12 (1): 9-22.","journal-title":"Cancer Cell"},{"issue":"10","key":"1674_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","volume":"13","author":"GC Chiang","year":"2007","unstructured":"Chiang GC, Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007, 13 (10): 433-442.","journal-title":"Trends Mol Med"},{"issue":"11","key":"1674_CR41","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nrd3531","volume":"10","author":"D Benjamin","year":"2011","unstructured":"Benjamin D, Colombi M, Moroni C, Hall MN: Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011, 10 (11): 868-880.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1674_CR42","doi-asserted-by":"publisher","first-page":"e32516","DOI":"10.1371\/journal.pone.0032516","volume":"7","author":"M Kurdi\u00e1n","year":"2012","unstructured":"Kurdi\u00e1n M, Herrero-Fresneda I, Lloberas N, Gimenez-Bonafe P, Coria V, Grande MT, Boggia J, Malacrida L, Torras J, Ar\u00e9valo MA, Gonz\u00e1lez-Mart\u00ednez F, L\u00f3pez-Novoa JM, Griny\u00f3 J, Noboa O: Delayed mTOR inhibition with low dose of everolimus reduces TGF\u03b2 expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One. 2012, 7 (3): e32516-","journal-title":"PLoS One"},{"issue":"5","key":"1674_CR43","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/ki.2010.457","volume":"79","author":"EK Geissler","year":"2011","unstructured":"Geissler EK, Schlitt HJ: MTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int. 2011, 79 (5): 502-511.","journal-title":"Kidney Int"},{"issue":"1","key":"1674_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/01.tp.0000296831.91303.9a","volume":"85","author":"P Pontrelli","year":"2008","unstructured":"Pontrelli P, Rossini M, Infante B, Stallone G, Schena A, Loverre A, Ursi M, Verrienti R, Maiorano A, Zaza G, Ranieri E, Gesualdo L, Ditonno P, Bettocchi C, Schena FP, Grandaliano G: Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation. 2008, 85 (1): 125-134.","journal-title":"Transplantation"},{"issue":"4","key":"1674_CR45","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","volume":"8","author":"M Breuleux","year":"2009","unstructured":"Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA: Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition. Mol Cancer Ther. 2009, 8 (4): 742-753.","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"1674_CR46","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","volume":"26","author":"X Wan","year":"2007","unstructured":"Wan X, Harkavy B, Shen N, Grohar P, Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007, 26 (13): 1932-1940.","journal-title":"Oncogene"},{"issue":"4","key":"1674_CR47","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.devcel.2007.03.020","volume":"12","author":"PT Bhaskar","year":"2007","unstructured":"Bhaskar PT, Hay N: The two TORCs and Akt. Dev Cell. 2007, 12 (4): 487-502.","journal-title":"Dev Cell"},{"issue":"21","key":"1674_CR48","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","volume":"18","author":"BM Slomovitz","year":"2012","unstructured":"Slomovitz BM, Coleman RL: The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012, 18 (21): 5856-5864.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1674_CR49","first-page":"2658","volume":"63","author":"C Gilles","year":"2003","unstructured":"Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM: Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003, 63 (10): 2658-2664.","journal-title":"Cancer Res"},{"issue":"3","key":"1674_CR50","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O\u2019Reilly","year":"2006","unstructured":"O\u2019Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66 (3): 1500-1508.","journal-title":"Cancer Res"},{"issue":"16","key":"1674_CR51","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65 (16): 7052-7058.","journal-title":"Cancer Res"},{"issue":"10","key":"1674_CR52","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell A, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008, 26 (10): 1588-1595.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1674_CR53","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","volume":"64","author":"A Boulay","year":"2004","unstructured":"Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O\u2019Reilly T, Stolz B, Marti A, Thomas G, Lane HA: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004, 64 (1): 252-261.","journal-title":"Cancer Res"},{"issue":"10","key":"1674_CR54","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","volume":"26","author":"C Tanaka","year":"2008","unstructured":"Tanaka C, O\u2019Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA: Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008, 26 (10): 1596-1602.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1674_CR55","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.4161\/cbt.5.9.3151","volume":"5","author":"M Katoh","year":"2006","unstructured":"Katoh M, Katoh M: Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther. 2006, 5 (9): 1059-1064.","journal-title":"Cancer Biol Ther"},{"issue":"50","key":"1674_CR56","doi-asserted-by":"publisher","first-page":"7443","DOI":"10.1038\/sj.onc.1209091","volume":"24","author":"L Larue","year":"2005","unstructured":"Larue L, Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3\u2032 kinase\/AKT pathways. Oncogene. 2005, 24 (50): 7443-7454.","journal-title":"Oncogene"},{"key":"1674_CR57","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1471-2407-9-304","volume":"9","author":"V Masola","year":"2009","unstructured":"Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M: Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer. 2009, 9: 304-","journal-title":"BMC Cancer"},{"issue":"3","key":"1674_CR58","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1172\/JCI13662","volume":"108","author":"I Vlodavsky","year":"2001","unstructured":"Vlodavsky I, Friedmann Y: Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest. 2001, 108 (3): 341-347.","journal-title":"J Clin Invest"},{"issue":"11","key":"1674_CR59","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1007\/s00018-008-7584-6","volume":"65","author":"NJ Nasser","year":"2008","unstructured":"Nasser NJ: Heparanase involvement in physiology and disease. Cell Mol Life Sci. 2008, 65 (11): 1706-1715.","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"1674_CR60","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1582-4934.2007.00039.x","volume":"11","author":"V Vreys","year":"2007","unstructured":"Vreys V, David G: Mammalian heparanase: what is the message?. J Cell Mol Med. 2007, 11 (3): 427-452.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"1674_CR61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00005-009-0061-6","volume":"58","author":"M Szymczak","year":"2010","unstructured":"Szymczak M, Kuzniar J, Klinger M: The role of heparanase in diseases of the glomeruli. Arch Immunol Ther Exp (Warsz). 2010, 58 (1): 45-56.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"16","key":"1674_CR62","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1101\/gad.12.16.2445","volume":"12","author":"M Whitman","year":"1998","unstructured":"Whitman M: Smads and early developmental signaling by the TGFbeta superfamily. Genes Dev. 1998, 12 (16): 2445-2462.","journal-title":"Genes Dev"},{"issue":"2","key":"1674_CR63","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/cr.2009.5","volume":"19","author":"J Xu","year":"2009","unstructured":"Xu J, Lamouille S, Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19 (2): 156-172.","journal-title":"Cell Res"},{"issue":"1","key":"1674_CR64","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2337\/db10-0892","volume":"60","author":"B Wang","year":"2011","unstructured":"Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, Jandeleit-Dahm K, Burns WC, Thomas MC, Cooper ME, Kantharidis P: miR-200a Prevents renal fibrogenesis through repression of TGF-\u03b22 expression. Diabetes. 2011, 60 (1): 280-287.","journal-title":"Diabetes"},{"issue":"3","key":"1674_CR65","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1210\/endo.141.3.7359","volume":"141","author":"C Hill","year":"2000","unstructured":"Hill C, Flyvbjerg A, Gr\u00f8nbaek H, Petrik J, Hill DJ, Thomas CR, Sheppard MC, Logan A: The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology. 2000, 141 (3): 1196-1208.","journal-title":"Endocrinology"},{"issue":"3","key":"1674_CR66","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1677\/joe.0.1700647","volume":"170","author":"C Hill","year":"2001","unstructured":"Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A: Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol. 2001, 170 (3): 647-651.","journal-title":"J Endocrinol"},{"issue":"2","key":"1674_CR67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1681\/ASN.2011070645","volume":"23","author":"J Chen","year":"2012","unstructured":"Chen J, Chen JK, Nagai K, Plieth D, Tan M, Lee TC, Threadgill DW, Neilson EG, Harris RC: EGFR signaling promotes TGF\u03b2-dependent renal fibrosis. J Am Soc Nephrol. 2012, 23 (2): 215-224.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1674_CR68","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1177\/1535370213498976","volume":"238","author":"X Xu","year":"2013","unstructured":"Xu X, Wan X, Geng J, Li F, Yang T, Dai H: Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Exp Biol Med (Maywood). 2013, 238 (9): 1082-1094.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1674_CR69","doi-asserted-by":"publisher","first-page":"403280","DOI":"10.1155\/2013\/403280","volume":"2013","author":"G Zaza","year":"2013","unstructured":"Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A: Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol. 2013, 2013: 403280-","journal-title":"Clin Dev Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-11-292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:52:12Z","timestamp":1630551132000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-11-292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,20]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1674"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-11-292","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,20]]},"assertion":[{"value":"5 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"292"}}